酶活性作为糖尿病血管病变的预测指标。

Enzyme activities as a predictor of diabetic vasculopathy.

作者信息

Camerini-Davalos R A, Velasco C A, Glasser M, Bloodworth J M

出版信息

Am J Med. 1986 Apr;80(4):574-82. doi: 10.1016/0002-9343(86)90810-7.

Abstract

Forty-one patients with chemical diabetes had three oral glucose tolerance tests and underwent muscle biopsy three times over a period of three years. Twenty-three received glipizide and 18 placebo. Those taking placebo had an increase in the mean muscle capillary basement membrane width (p = 0.01), but those taking glipizide showed a decrease (p = 0.01) to values no different from those of nondiabetic subjects. Determinations of enzyme activities involved in the synthesis and degradation of glycoproteins revealed a three-year decrease (not significant) in muscle glucosyltransferase activity in the glipizide-treated patients, but a statistically significant difference (p less than 0.01) comparing the adjusted means of the two treatment groups. N-acetyl-beta-glucosaminidase activity was significantly increased in muscle from baseline values (p less than 0.01), with adjusted means also significantly different (p less than 0.01). The data suggest that changes in basement membrane and enzyme activities are correlated, and the latter may be a predictor to follow the development, progression, or regression of diabetic vasculopathy.

摘要

41例化学性糖尿病患者在三年时间内进行了三次口服葡萄糖耐量试验，并接受了三次肌肉活检。23例患者服用格列吡嗪，18例服用安慰剂。服用安慰剂的患者肌肉毛细血管基底膜平均宽度增加（p = 0.01），而服用格列吡嗪的患者则出现下降（p = 0.01），降至与非糖尿病受试者无异的值。对参与糖蛋白合成和降解的酶活性的测定显示，格列吡嗪治疗的患者肌肉葡萄糖基转移酶活性在三年内有所下降（无统计学意义），但两个治疗组调整后的均值存在统计学显著差异（p < 0.01）。N - 乙酰 - β - 葡萄糖苷酶活性较基线值显著增加（p < 0.01），调整后的均值也有显著差异（p < 0.01）。数据表明，基底膜变化与酶活性相关，后者可能是追踪糖尿病血管病变发展、进展或消退的一个预测指标。